Isomorphic Labs and MSD Enter Strategic Research Collaboration

LONDON, November, 19 2026 - Isomorphic Labs, an AI-first drug design and development company, and MSD, trade name of Merck & Co., Inc., Rahway, NJ, USA, today announced a research collaboration that brings together Isomorphic Labs' AI approach to drug discovery with MSD's rich proprietary data resources and deep discovery experience.

The companies will collaborate to discover therapeutic small molecule candidates against an oncology target of strategic importance. Isomorphic Labs will perform *in silico* predictions and deliver molecular designs, applying its proprietary drug design engine (IsoDDE) incorporating select high-quality proprietary data sets supplied by MSD for the purpose of this collaboration. MSD will be responsible for preclinical and clinical development, as well as manufacturing and commercialisation of any products derived from the collaboration.

Under the terms of the agreement, Isomorphic Labs will receive an upfront payment from MSD and be eligible for payments based on the achievement of specified research, development, regulatory and commercial milestones, as well as tiered royalties on net sales. Isomorphic Labs also receives an option to co-fund development activities in return for elevated royalties.

"Through this collaboration with MSD, we will apply our world-leading drug design engine to unlock significant discovery progress," said Sarah Skerratt, Chief Research Officer, Isomorphic Labs. "By leveraging the generative and predictive power of the IsoDDE to address this challenging program, this collaboration highlights our companies' shared commitment to innovation for the benefit of patient populations with unmet needs."

"The key to successfully leveraging AI/ML for molecular invention lies in close coordination of wet-lab and dry-lab functions," said George Addona, senior vice president and head of Discovery, Preclinical Development and Translational Medicine, MSD Research Laboratories. "By combining MSD's substantial internal data capabilities and discovery expertise with Isomorphic Labs' powerful modeling and compute capabilities, we aim to identify new ways to design and create better candidates faster."

The collaboration highlights the transformative power of bringing together advanced AI, unique data sets and established biopharmaceutical leadership to accelerate the advancement of therapeutic candidates, navigating complex biology with unprecedented speed and precision.

About Isomorphic Labs

Isomorphic Labs was founded in 2021, to transform drug discovery with the power of artificial intelligence, ushering in a new era of biomedical breakthroughs. Isomorphic Labs is led by CEO Sir Demis Hassabis and President Max Jaderberg. Isomorphic Labs has built a world-leading, modality-agnostic drug design engine (IsoDDE) comprised of

foundational AI models. The computational drug-design system provides the predictive fidelity required to navigate novel biological systems with unprecedented accuracy.

The company is continually innovating on model architecture and developing cutting-edge capabilities to advance drug design. Isomorphic Labs is headquartered in London and has office locations in Cambridge, Massachusetts and Lausanne, Switzerland. Isomorphic Labs is advancing a broad and ambitious drug design portfolio through partnered programs and whollyowned internal programs. For more information, go to www.isomorphiclabs.com and follow us on LinkedIn and X.